RxDoctor Payments Data

Michelle Dyess, PA

Medical · Baton Rouge, LANPI 1609276161

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Abbott at 24.1% of the total.

$3,245in general payments, 2019–2025

Across 145 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$781
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$320
  • Ipsen Biopharmaceuticals, Inc$278
  • IBSA Pharma Inc.$276
  • Merz Pharmaceuticals, LLC$241
  • Collegium Pharmaceutical, Inc.$172
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,245 in reported general payments places this provider in the 80th percentile of 253 medical providers in Louisiana.

See all medical providers in Louisiana

Medicare billing

Part B allowed, 2024
$37,241
Medicare patients
257
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate16$7,466
Tizanidine Hcl215$3,434
Methocarbamol266$2,814
Lidocaine14$2,763
Gabapentin163$1,446
Baclofen115$1,228
Duloxetine Hcl77$1,092
Diclofenac Sodium18$991
Cyclobenzaprine Hcl138$845
Celecoxib49$636
Amitriptyline Hcl39$622
Nabumetone43$530
Ibuprofen40$303
Meloxicam125$256
Naproxen16$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$81$7,46616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 253 medical providers in Louisiana.

Other medical in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →